ApoA-1 infusion reduces arterial cholesterol and myocardial lesions in a rat model of cardiac dysfunction and insulin resistance
MetadataShow full item record
OBJECTIVE Low plasma high-density lipoprotein cholesterol (HDL-C) concentration is associated with the metabolic syndrome (MetS) and increased prevalence of cardiovascular disease (CVD). Animal and human studies report infusion of apolipoprotein A-1 (apoA-1) can reduce endothelial dysfunction, and/or induce regression of atherosclerosis. However, the direct mechanisms underlying the vascular benefits of either apoA-1 or HDL-C remain unclear. In this study, we assessed the ability of reconstituted HDL (rHDL) to improve vascular complications of MetS, including left ventricular (LV)-hypertrophy, arterial cholesterol deposition and myocardial lesion development. METHODS AND RESULTS Obese insulin resistant (IR) JCR:LA-cp rats were infused with rHDL (0.4 mg/kg) over 3 days before assessing cardiac function (Echocardiography) at days 7 and 50 post-infusion, as well as haematoxylin and eosin staining of myocardial lesions at day 50. Acute ex vivo arterial cholesterol deposition was assessed with acute infusion of rHDL ex-vivo. Infusion of rHDL partially corrected abnormal diastolic compliance (18%; *p < 0.05) and improved parameters of cardiac function in IR rats. Further, acute rHDL infusion in carotid vessels reduced remnant lipoprotein associated-cholesterol deposition (30–86%; **p < 0.01) ex vivo in IR and male Wistar rats and reduced (41%; *p < 0.05) the frequency of early-stage myocardial lesions in IR rats. CONCLUSION Short-term infusion of rHDL may beneficially reduce chronic vascular sequelae of MetS, including temporary improvement in LV-dysfunction, acute reduction of acute arterial cholesterol deposition and the development of early-stage myocardial lesions in the JCR:LA-cp rat.
Showing items related by title, author, creator and subject.
Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline CharacteristicsLonn, E.; Bosch, J.; Pogue, J.; Avezum, A.; Chazova, I.; Dans, A.; Diaz, R.; Fodor, G.; Held, C.; Jansky, P.; Keltai, M.; Keltai, K.; Kunti, K.; Kim, J.; Leiter, L.; Lewis, B.; Liu, L.; Lopez-Jaramillo, P.; Pais, P.; Parkhomenko, A.; Peters, R.; Piegas, L.; Reid, Christopher; Sliwa, K.; Toff, W.; Varigos, J.; Xavier, D.; Yusoff, K.; Zhu, J.; Dagenais, G.; Yusuf, S.; HOPE-3 Investigators (2015)BACKGROUND: Cholesterol and blood pressure (BP) can be effectively and safely lowered with statin drugs and BP-lowering drugs, reducing major cardiovascular (CV) events by 20%-30% within 5 years in high-risk individuals. ...
Ammirati, E.; Cianflone, D.; Vecchio, V.; Banfi, M.; Vermi, A.; De Metrio, M.; Grigore, L.; Pellegatta, F.; Pirillo, A.; Garlaschelli, K.; Manfredi, A.; Catapano, A.; Maseri, A.; Palini, A.; Norata, Giuseppe (2012)Background- Adaptive T-cell response is promoted during atherogenesis and results in the differentiation of näive CD4 + T cells to effector and/or memory cells of specialized T-cell subsets. Aim of this work was to ...
Vascular pentraxin 3 controls arterial thrombosis by targeting collagen and fibrinogen induced platelets aggregationBonacina, F.; Barbieri, S.; Cutuli, L.; Amadio, P.; Doni, A.; Sironi, M.; Tartari, S.; Mantovani, A.; Bottazzi, B.; Garlanda, C.; Tremoli, E.; Catapano, A.; Norata, Giuseppe (2016)© 2016 The Authors. Aim: The long pentraxin PTX3 plays a non-redundant role during acute myocardial infarction, atherosclerosis and in the orchestration of tissue repair and remodeling during vascular injury, clotting and ...